Drug Shortage Report for IMIPENEM AND CILASTATIN FOR INJECTION USP
Report ID | 144424 |
Drug Identification Number | 02358336 |
Brand name | IMIPENEM AND CILASTATIN FOR INJECTION USP |
Common or Proper name | IMIPENEM AND CILASTATIN FOR INJECTION USP |
Company Name | SANDOZ CANADA INCORPORATED |
Market Status | MARKETED |
Active Ingredient(s) | CILASTATIN IMIPENEM |
Strength(s) | 250MG 250MG |
Dosage form(s) | POWDER FOR SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 10PSOIJ CA |
ATC code | J01DH |
ATC description | OTHER BETA-LACTAM ANTIBACTERIALS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2021-08-20 |
Estimated end date | Unknown |
Actual end date | 2023-10-26 |
Shortage status | Resolved |
Updated date | 2023-10-27 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2023-10-27 | English | Compare |
v5 | 2023-10-26 | French | Compare |
v4 | 2023-10-26 | English | Compare |
v3 | 2023-10-26 | English | Compare |
v2 | 2021-08-23 | French | Compare |
v1 | 2021-08-23 | English | Compare |
Showing 1 to 6 of 6